The J&J Lesson
J&J's exit from the coronary angioplasty market was a sign of the end of an era. Without a product at the high end of innovation, it was left with a basic product that in the interim had become commoditized.
You may also be interested in...
There has been a fundamental structural shift in the US medical device industry; economics are the driving force as early-stage financing has dried up, reimbursements have been steadily reduced and hospitals and clinics are forced to operate more efficiently. Technology Commercialization Group (TCG) looks at these changes and the implications for both large and small companies.